GlassScriptPhysician profile
Lauren Stone
NPI 1104558857
$5,753.62
in general payments reported to CMS, 2019-2025
51 companies · $1,925 in 2025
The $1,925 reported for 2025 was more than what 95% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $444 · 2023: $1,523 · 2024: $1,861 · 2025: $1,925.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,310.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,309.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $531.83 | 2022-2025 | |
| Daiichi Sankyo INC. | $468.54 | 2022-2025 | Enhertu, Datroway |
| Merck Sharp & Dohme LLC | $452.35 | 2022-2025 | Keytruda, Lynparza, Welireg |
| Celgene Corporation | $424.02 | 2022-2025 | Reblozyl, Pomalyst, Opdualag |
| E.R. Squibb & Sons, L.L.C. | $363.17 | 2023-2025 | Opdivo, Opdualag |
| Astrazeneca Pharmaceuticals LP | $344.46 | 2022-2025 | Imfinzi, Enhertu, Calquence |
| Incyte Corporation | $319.51 | 2022-2025 | Jakafi, Monjuvi, Pemazyre |
| Abbvie INC. | $256.45 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $241.76 | 2023-2025 | Fruzaqla, Ninlaro |
| Array Biopharma INC | $220.85 | 2022-2025 | Lorbrena, Braftovi, Mektovi |
| Pfizer INC. | $199.97 | 2023-2025 | |
| Lilly USA, LLC | $118.41 | 2022-2024 | Verzenio, Jaypirca, Retevmo |
| Rigel Pharmaceuticals, INC. | $102.99 | 2022-2024 | Tavalisse, Rezlidhia |
| Eisai INC. | $102.68 | 2022-2025 | |
| Janssen Biotech, INC. | $99.64 | 2022-2025 | Rybrevant, Talvey, Darzalex |
Show all 51 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lauren Stone listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.